Find Camizestrant manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

0

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Azd-9833, Unii-jup57a8epz, Azd9833, 2222844-89-3, Camizestrant [usan], Jup57a8epz
Molecular Formula
C24H28F4N6
Molecular Weight
476.5  g/mol
InChI Key
WDHOIABIERMLGY-CMJOXMDJSA-N
FDA UNII
JUP57A8EPZ

Camizestrant
Camizestrant is an orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.
1 2D Structure

Camizestrant

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
2.1.2 InChI
InChI=1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1
2.1.3 InChI Key
WDHOIABIERMLGY-CMJOXMDJSA-N
2.1.4 Canonical SMILES
CC1CC2=C(C=CC3=C2C=NN3)C(N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF
2.1.5 Isomeric SMILES
C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF
2.2 Other Identifiers
2.2.1 UNII
JUP57A8EPZ
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Azd-9833

2. Azd9833

3. N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo(4,3-f)isoquinolin-6-yl)pyridin-3-amine

2.3.2 Depositor-Supplied Synonyms

1. Azd-9833

2. Unii-jup57a8epz

3. Azd9833

4. 2222844-89-3

5. Camizestrant [usan]

6. Jup57a8epz

7. Az14066724

8. Az-14066724

9. N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine

10. 3-pyridinamine, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-

11. Camizestrant [inn]

12. Camizestrant [who-dd]

13. Chembl4650365

14. Schembl20089710

15. Ex-a5025

16. Nsc828717

17. Who 11592

18. At22885

19. Nsc-828717

20. Hy-136255

21. Cs-0121043

22. N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine

23. N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6s,8r)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine

2.4 Create Date
2018-06-23
3 Chemical and Physical Properties
Molecular Weight 476.5 g/mol
Molecular Formula C24H28F4N6
XLogP34.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count7
Exact Mass476.23115757 g/mol
Monoisotopic Mass476.23115757 g/mol
Topological Polar Surface Area60.1 Ų
Heavy Atom Count34
Formal Charge0
Complexity674
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Cambrex Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SCOPE Summit
Not Confirmed
arrow

Cambrex Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
SCOPE Summit
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

SCOPE Summit
Not Confirmed
arrow
arrow
SCOPE Summit
Not Confirmed

CAMIZESTRANT

NDC Package Code : 59116-7280

Start Marketing Date : 2023-06-13

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Camizestrant is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.


Lead Product(s): Camizestrant,Ribociclib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 26, 2025

blank

01

MEDSIR

Spain
arrow
SCOPE Summit
Not Confirmed

MEDSIR

Spain
arrow
SCOPE Summit
Not Confirmed

Details : Camizestrant is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 26, 2025

blank

Details:

AZD9833 (camizestrant) is an investigational, potent, next-generation oral SERD and ER antagonist that is currently being investigated for the treatment of HR-positive breast cancer.


Lead Product(s): Camizestrant,Palbociclib,Ribociclib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 26, 2025

blank

02

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Details : AZD9833 (camizestrant) is an investigational, potent, next-generation oral SERD and ER antagonist that is currently being investigated for the treatment of HR-positive breast cancer.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 26, 2025

blank

Details:

Midazolam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Midazolam,Camizestrant,Carbamazepine

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 09, 2024

blank

03

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Details : Midazolam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

August 09, 2024

blank

Details:

Saruparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.


Lead Product(s): Saruparib,Camizestrant

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 24, 2024

blank

04

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Details : Saruparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 24, 2024

blank

Details:

Camizestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.


Lead Product(s): Camizestrant,Abemaciclib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Austrian Breast & Colorectal Cancer Study Group

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 19, 2023

blank

05

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Lead Product(s) : Camizestrant,Abemaciclib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Austrian Breast & Colorectal Cancer Study Group

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Camizestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 19, 2023

blank

Details:

Camizestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.


Lead Product(s): Camizestrant,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 30, 2023

blank

06

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Details : Camizestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 30, 2023

blank

Details:

Camizestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.


Lead Product(s): Camizestrant,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 20, 2023

blank

07

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Details : Camizestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 20, 2023

blank

Details:

Camizestrant (AZD9833) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.


Lead Product(s): Camizestrant,Palbociclib,Undisclosed

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 08, 2022

blank

08

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Details : Camizestrant (AZD9833) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 08, 2022

blank

Details:

AZD9833 (camizestrant) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.


Lead Product(s): Camizestrant,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 26, 2022

blank

09

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Details : AZD9833 (camizestrant) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 26, 2022

blank

Details:

Camizestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Camizestrant,Itraconazole

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Parexel

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 23, 2022

blank

10

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

AstraZeneca

United Kingdom
arrow
SCOPE Summit
Not Confirmed

Details : Camizestrant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 23, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 2222844-89-3 / Camizestrant API manufacturers, exporters & distributors?

Camizestrant manufacturers, exporters & distributors 1

99

PharmaCompass offers a list of Camizestrant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Camizestrant manufacturer or Camizestrant supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Camizestrant manufacturer or Camizestrant supplier.

PharmaCompass also assists you with knowing the Camizestrant API Price utilized in the formulation of products. Camizestrant API Price is not always fixed or binding as the Camizestrant Price is obtained through a variety of data sources. The Camizestrant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Camizestrant

Synonyms

Azd-9833, Unii-jup57a8epz, Azd9833, 2222844-89-3, Camizestrant [usan], Jup57a8epz

Cas Number

2222844-89-3

Unique Ingredient Identifier (UNII)

JUP57A8EPZ

About Camizestrant

Camizestrant is an orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.

Camizestrant Manufacturers

A Camizestrant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Camizestrant, including repackagers and relabelers. The FDA regulates Camizestrant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Camizestrant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Camizestrant Suppliers

A Camizestrant supplier is an individual or a company that provides Camizestrant active pharmaceutical ingredient (API) or Camizestrant finished formulations upon request. The Camizestrant suppliers may include Camizestrant API manufacturers, exporters, distributors and traders.

click here to find a list of Camizestrant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Camizestrant NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Camizestrant as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Camizestrant API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Camizestrant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Camizestrant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Camizestrant NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Camizestrant suppliers with NDC on PharmaCompass.

Camizestrant GMP

Camizestrant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Camizestrant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Camizestrant GMP manufacturer or Camizestrant GMP API supplier for your needs.

Camizestrant CoA

A Camizestrant CoA (Certificate of Analysis) is a formal document that attests to Camizestrant's compliance with Camizestrant specifications and serves as a tool for batch-level quality control.

Camizestrant CoA mostly includes findings from lab analyses of a specific batch. For each Camizestrant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Camizestrant may be tested according to a variety of international standards, such as European Pharmacopoeia (Camizestrant EP), Camizestrant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Camizestrant USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty